Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

A Phase IIa, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy With BMS-936557 in Subjects With Active Crohn's Disease

The purpose of this study is to determine whether BMS-936557 is effective for the treatment of moderate to severely active Crohn's Disease in patients who have had insufficient response and/or intolerance to conventional therapy for Crohn's Disease.

Anti-IP10: Anti Interferon-inducible ligand 10

Inclusion Criteria:

• Adults subjects with confirmed Crohn's Disease (CD) for at least 3 months
• Moderate to severely active CD as defined by Crohn's Disease Activity Index (CDAI) 220 to 450
• In the past have had insufficient response and or intolerance to ≥ 1 of the conventional therapy (immunosuppressants, corticosteroids and/or approved biologic therapy)

Exclusion Criteria:

• Ulcerative colitis (UC) or indeterminate colitis
• Short bowel syndrome
• Known stricture or noninflammatory stenosis leading to symptoms of obstruction
• Current stoma or current need for colostomy or ileostomy